Investors

Press Releases

Press Releases

Press Releases

September 13, 2021
STOUGHTON, Mass. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were
September 1, 2021
STOUGHTON, Mass. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the
August 16, 2021
STOUGHTON, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $100 million of the
August 5, 2021
– Xtampza ® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 – – Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million – – Full-Year 2021 Product Revenue Guidance Updated – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Aug.
June 16, 2021
STOUGHTON, Mass. , June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications
May 20, 2021
STOUGHTON, Mass. , May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference: Jefferies
May 6, 2021
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta ® Franchise and Adjusted EBITDA 2021 Guidance Range Raised   – – Colleen Tupper Appointed as Next CFO;  Paul Brannelly will be Leaving the Company to Pursue Other Opportunities   – –
February 25, 2021
– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition – – Collegium Reiterates Previously Issued 2021 Guidance   – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Collegium
January 6, 2021
– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta ® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million – STOUGHTON, Mass. , Jan.